MV BioTherapeutics presented at the 7th Microbiome Movement – Drug Development Europe

Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 7th Microbiome Movement – Drug Development Summit Europe 2023 being held in London during January 31st-February 2nd, 2023. The presentation has been included in the second day of the conference at 14.00. Reprogramming the Microbiome in Cancer Immunotherapy Outlining the adaptive modulation of…

Apyrase-mediated amplification of secretory IgA promotes intestinal homeostasis

Cell Reports, July 19 2022 Secretory immunoglobulin A (SIgA) interaction with commensal bacteria conditions microbiota composition and function. However, mechanisms regulating reciprocal control of microbiota and SIgA are not defined. Bacteria-derived adenosine triphosphate (ATP) limits T follicular helper (Tfh) cells in the Peyer’s patches (PPs) via P2X7 receptor (P2X7R) and thereby SIgA generation. Here we…

MV BioTherapeutics to present at the 6th Microbiome Movement – Drug Development Europe

Bellinzona, November 2021 We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 6thMicrobiome Movement – Drug Development Summit Europe 2022 in London during January 25th-27th, 2022. The presentation has been included in stream A titled “Understanding mechanisms of action & preclinical development” the 26th at 13.45.…

MV BioTherapeutics ApyraVax

MV Biotherapeutics and Malcisbo agree to explore the Apyrase technology platform for AH Vaccines

Bellinzona – Schlieren, March  2021 MV Biotherapeutics SA (from now on “MV Bio”), a Swiss microbiome biotherapeutics company and Malcisbo AG (from now on “Malcisbo”), a Swiss company developing carbohydrate-based vaccines are proud to announce a collaboration after winning an Innosuisse grant. Malcisbo and MV Bio have previously signed a contract, which gives Malcisbo the…